Genmab
NASDAQ:GMABBiotechCopenhagen, Denmark, Denmark · Est. 1999 · 2,400 employees
Genmab is a Danish biotechnology company developing monoclonal antibody-based therapies for cancer, inflammation, and other diseases.
12
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
27
Indications↗
Distinct diseases across all programs
85
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
12 drugs in development
Phase 32
Phase 25
Phase 14
Preclinical7
By Therapeutic Area
top 2
Oncology
1179%
Hematology
17%
R&D Momentum
69/100
Pipeline Velocity
36/100
Trial Completion Rate
32/100
Pipeline Concentration
64/100
Pipeline Freshness
70/100
Strategic Signals
- ↗Active in Hematology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Terminated
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Jul 9, 2026
Terminated
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07)
Jul 9, 2026
Active, not recruiting
A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Jul 8, 2026
Recruiting
An Open-Label, Multicenter, First-in-Human Trial of GEN3018 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Jul 8, 2026
Recruiting
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Jul 8, 2026
Recruiting
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
Jul 8, 2026
Recruiting
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Jul 8, 2026
Recruiting
First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors
Jul 8, 2026
Active, not recruiting
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Jul 8, 2026
Active, not recruiting
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Details
Company Info
Company Overview
$19.0B
Mkt Cap
$2.5B
Revenue
—
Cash
CEOJan van de Winkel
Founded1999
Employees2,400
HQCopenhagen, Denmark, Denmark
ExchangeNASDAQ:GMAB
Websitegenmab.com
LinkedInCompany Page
Therapeutic Focus
HematologyOncologyImmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology(1 drug)
—
1
—
—
—
Hematology(1 drug)
Oncology(11 drugs)
7
3
5
2
—
Oncology(11 drugs)
Unknown / Other(2 drugs)
—
1
—
1
—
Unknown / Other(2 drugs)
Regulatory
Regulatory Timeline
20231 event
FDAMay 19
Epkinly — EPKINLY
Application BLA761324 (BLA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)